Biosimilars sales were $201.5 million, up 7% driven by Benepali, with sales of $125 million, up 16%. LEQEMBI global in-market sales in the quarter were approximately $87 million, including U.S.

TD Cowen analysts adjusted their outlook on Biogen (NASDAQ:BIIB) shares, reducing the price target to $200 from the previous $275, while sustaining a Buy rating on the stock. The revision reflects ...

Scotiabank lowered the firm’s price target on Biogen (BIIB) to $224 from $244 and keeps an Outperform rating on the shares. Fiscal year results ...

RBC Capital lowered the firm’s price target on Biogen (BIIB) to $225 from $231 but keeps an Outperform rating on the shares after its Q4 ...

Q4 2024 Earnings Call Transcript February 12, 2025 Operator: Good morning. My name is Jennifer and I will be your conference ...

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

Royalty Pharma has signed a deal to pay Biogen $250m to support the development of its late-stage experimental lupus ...

We think Biogen's neurology, immunology, and focus on rare diseases support a narrow moat. Biogen's strategy has its roots in the 2003 merger of Biogen (Avonex for treating multiple sclerosis, or MS) ...

At this time, I'd like to welcome everyone to the Biogen fourth-quarter and full-year 2024 earnings call and business update. (Operator Instructions) Today's conference is being recorded. Thank you. I ...

Catalent, a global contract development and manufacturing organization (CDMO), has been recognized with two awards in the 2024 Pharmaceutical Technology Excellence Awards in the Innovation and Social ...

Prostate cancer cells usually require male androgen hormones, such as testosterone, to grow. Androgen deprivation therapy ...

Biogen beat Q4 estimates with a 17% EPS rise and $2.46 billion in sales. The company expects revenue declines in 2025 as multiple sclerosis drug sales drop.